176 related articles for article (PubMed ID: 12109343)
21. Impact of biochemical recurrence in prostate cancer among US veterans.
Uchio EM; Aslan M; Wells CK; Calderone J; Concato J
Arch Intern Med; 2010 Aug; 170(15):1390-5. PubMed ID: 20696967
[TBL] [Abstract][Full Text] [Related]
22. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
23. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
24. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
25. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
Brenner H; Arndt V
J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
[TBL] [Abstract][Full Text] [Related]
27. The impact of PSA testing frequency on prostate cancer incidence and treatment in older men.
Shao YH; Albertsen PC; Shih W; Roberts CB; Lu-Yao GL
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):332-9. PubMed ID: 21709691
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
29. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Houston KA; King J; Li J; Jemal A
J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
[TBL] [Abstract][Full Text] [Related]
30. Prognostic features in men who died of prostate cancer.
Thompson KE; Hernández J; Canby-Hagino ED; Troyer D; Thompson IM
J Urol; 2005 Aug; 174(2):553-6; discussion 556. PubMed ID: 16006890
[TBL] [Abstract][Full Text] [Related]
31. Diagnosis, management and screening of early localised prostate cancer.
Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
[TBL] [Abstract][Full Text] [Related]
32. Unanswered questions in screening for prostate cancer.
Neal DE; Leung HY; Powell PH; Hamdy FC; Donovan JL
Eur J Cancer; 2000 Jun; 36(10):1316-21. PubMed ID: 10882874
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
[TBL] [Abstract][Full Text] [Related]
34. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
Hoffman RM; Koyama T; Albertsen PC; Barry MJ; Daskivich TJ; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Potosky AL; Penson DF
J Gen Intern Med; 2015 Jul; 30(7):924-34. PubMed ID: 25678374
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen testing of older men.
Carter HB; Landis PK; Metter EJ; Fleisher LA; Pearson JD
J Natl Cancer Inst; 1999 Oct; 91(20):1733-7. PubMed ID: 10528023
[TBL] [Abstract][Full Text] [Related]
36. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
37. Trends in prostate cancer in the United States.
Brawley OW
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):152-6. PubMed ID: 23271766
[TBL] [Abstract][Full Text] [Related]
38. [Adenocarcinoma of the prostate].
Dvorácek J
Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
[TBL] [Abstract][Full Text] [Related]
39. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program.
Smart CR
Cancer; 1997 Nov; 80(9):1835-44. PubMed ID: 9351557
[TBL] [Abstract][Full Text] [Related]
40. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
